Inclusion Criteria:

- ≥ 18 and ≤ 70 years of age

- Histologically confirmed advanced or metastatic adenocarcinoma of the stomach

- Have failed for 2 lines of chemotherapy

- Life expectancy of more than 3 months

- ECOG performance scale ≤ 2

- At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

- Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

- More than 4 weeks for operation or radiotherapy

- More than 4 weeks for cytotoxic agents or growth inhibitors

- Adequate hepatic, renal, heart, and hematologic functions (platelets > 80 × 109/L,
neutrophil > 2.0 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper
limit of normal(ULN), and serum transaminase≤2.5×the ULN).

Exclusion Criteria:

- Pregnant or lactating women

- History of other malignancies except cured basal cell carcinoma of skin and carcinoma
in-situ of uterine cervix

- Any factors that influence the usage of oral administration; Evidence of CNS
metastasis

- History of another malignancy within the last five years except cured basal cell
carcinoma of skin and carcinoma in-situ of uterine cervix

- Intercurrence with one of the following: hypertension, coronary artery disease,
arrhythmia and heart failure

- Receiving the therapy of thrombolysis or anticoagulation

- Abuse of alcohol or drugs

- Allergy to the ingredient of the agent or more than two kinds of food and drug

- Less than 4 weeks from the last clinical trial

- Disability of serious uncontrolled intercurrence infection.